Glatiramer acetate (also known as Copolymer 1, Cop-1), sold under the brand name Copaxone among others, is an immunomodulator medication used to treat multiple sclerosis.[1][2] Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability. While a conclusive diagnosis of multiple sclerosis requires a history of two or more episodes of symptoms and signs, glatiramer acetate is approved to treat a first episode anticipating a diagnosis. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.[1][2]
It is a mixture of random-sized peptides that are composed of the four amino acids found in myelin basic protein, namely glutamic acid, lysine, alanine, and tyrosine. Myelin basic protein is the antigen in the myelin sheaths of the neurons that stimulates an autoimmune reaction in people with MS, so the peptide may work as a decoy for the attacking immune cells.
It is on the World Health Organization's List of Essential Medicines.[6]
^ abcd"Copaxone- glatiramer acetate injection, solution". DailyMed. 23 July 2020. Retrieved 11 November 2020.
^ abcd"Glatopa- glatiramer acetate injection, solution". DailyMed. 31 July 2020. Retrieved 11 November 2020.
^"Neurological therapies". Health Canada. 9 May 2018. Retrieved 13 April 2024.
^"Brabio 20 mg/mL Solution for Injection, Pre-filled Syringe - Summary of Product Characteristics (SmPC)". (emc). Retrieved 11 November 2020.
^"Copaxone 20 mg/ml solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 29 September 2020. Retrieved 11 November 2020.
^World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
and 24 Related for: Glatiramer acetate information
Glatirameracetate (also known as Copolymer 1, Cop-1), sold under the brand name Copaxone among others, is an immunomodulator medication used to treat...
modestly effective at decreasing the number of attacks. Interferons and glatirameracetate are first-line treatments and are roughly equivalent, reducing relapses...
ocrelizumab, ofatumumab, and ublituximab; and immunomodulators: glatirameracetate, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, and diroximel...
Betaseron competes with other injectable forms of interferon beta, glatirameracetate, and a variety of newer multiple sclerosis drugs, some of which can...
with marketing partner Alvogen, multiple sclerosis treatment drug glatirameracetate in partnership with Mylan, and hepatitis C drugs under a licensing...
the treatment of asthma and COPD. GA Depot (long-acting version of glatirameracetate): In August 2023, received New Drug Application acceptance from the...
exactly which cells produce IL-1β. Treatment of multiple sclerosis with glatirameracetate or natalizumab has also been shown to reduce the presence of IL-1β...
"Oligodendrogenesis and myelinogenesis during postnatal development effect of glatirameracetate". Glia. 62 (4): 649–665. doi:10.1002/glia.22632. PMID 24481644. S2CID 25559134...
Current treatments for multiple sclerosis include interferon-B, Glatirameracetate, and Mitoxantrone, which function by reducing or inhibiting T Cell...
number of medications used to treat multiple sclerosis including glatirameracetate. Lyme disease Skin lesion Tick bite Rapini, Ronald P.; Bolognia, Jean...
generics. In one case, product hopping of the multiple sclerosis drug glatirameracetate (Copaxone) led to a cost to consumers of $4.3 to 6.5 billion dollars...
treatment of multiple sclerosis called Copolymer 1. Its chemical name is glatirameracetate. It was submitted by the TEVA Pharmaceutical Company to the FDA for...
migraine except as a last resort. Don't prescribe interferon-beta or glatirameracetate to patients with disability from progressive, non-relapsing forms...
It has been reported that an approved medication for MS treatment Glatirameracetate increases Breg frequencies and enhances their function. Similarly...
Bardens, Jenny; Bernard, Jacqueline T (2016). "Estriol combined with glatirameracetate for women with relapsing-remitting multiple sclerosis: a randomised...
lesions is unknown. The main ones are Interferon beta (IFN-beta), Glatirameracetate and Mitoxantrone[citation needed] Plasma exchange has been reported...
(2005). "Nasal vaccination with a proteosome-based adjuvant and glatirameracetate clears β-amyloid in a mouse model of Alzheimer disease". Journal of...
most likely responsive to immunomodulation with interferon-beta or glatirameracetate. People non-responsive to interferons are the most responsive to Copaxone...
(August 2018). "Different clinical response to interferon beta and glatirameracetate related to the presence of oligoclonal IgM bands in CSF in multiple...
Global Information
(what is this?) (verify)